These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31131705)

  • 1. Robust designs accounting for model uncertainty in longitudinal studies with binary outcomes.
    Seurat J; Nguyen TT; Mentré F
    Stat Methods Med Res; 2020 Mar; 29(3):934-952. PubMed ID: 31131705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust designs in longitudinal studies accounting for parameter and model uncertainties - application to count data.
    Loingeville F; Nguyen TT; Riviere MK; Mentré F
    J Biopharm Stat; 2020; 30(1):31-45. PubMed ID: 31032703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust and Adaptive Two-stage Designs in Nonlinear Mixed Effect Models.
    Fayette L; Leroux R; Mentré F; Seurat J
    AAPS J; 2023 Jul; 25(4):71. PubMed ID: 37466809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
    Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
    Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finding optimal design in nonlinear mixed effect models using multiplicative algorithms.
    Seurat J; Tang Y; Mentré F; Nguyen TT
    Comput Methods Programs Biomed; 2021 Aug; 207():106126. PubMed ID: 34038863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect models.
    Riviere MK; Ueckert S; Mentré F
    Biostatistics; 2016 Oct; 17(4):737-50. PubMed ID: 27166250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A generalisation of T-optimality for discriminating between competing models with an application to pharmacokinetic studies.
    Vajjah P; Duffull SB
    Pharm Stat; 2012; 11(6):503-10. PubMed ID: 23059829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal flexible sample size design with robust power.
    Zhang L; Cui L; Yang B
    Stat Med; 2016 Aug; 35(19):3385-96. PubMed ID: 26999385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
    Retout S; Mentré F; Bruno R
    Stat Med; 2002 Sep; 21(18):2623-39. PubMed ID: 12228881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design optimisation for pharmacokinetic modeling of a cocktail of phenotyping drugs.
    Nguyen TT; Bénech H; Delaforge M; Lenuzza N
    Pharm Stat; 2016; 15(2):165-77. PubMed ID: 26689604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.
    Tod M; Rocchisani JM
    J Pharmacokinet Biopharm; 1997 Aug; 25(4):515-37. PubMed ID: 9561492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model.
    Steven Ernest C; Nyberg J; Karlsson MO; Hooker AC
    J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):639-54. PubMed ID: 25308776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monte Carlo Simulations for the Analysis of Non-linear Parameter Confidence Intervals in Optimal Experimental Design.
    Krausch N; Barz T; Sawatzki A; Gruber M; Kamel S; Neubauer P; Cruz Bournazou MN
    Front Bioeng Biotechnol; 2019; 7():122. PubMed ID: 31179278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates.
    Retout S; Comets E; Samson A; Mentré F
    Stat Med; 2007 Dec; 26(28):5162-79. PubMed ID: 17486667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust population pharmacokinetic experiment design.
    Dodds MG; Hooker AC; Vicini P
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):33-64. PubMed ID: 16205840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A computer tool for a minimax criterion in binary response and heteroscedastic simple linear regression models.
    Casero-Alonso V; López-Fidalgo J; Torsney B
    Comput Methods Programs Biomed; 2017 Jan; 138():105-115. PubMed ID: 27886709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D-optimal designs of mean-covariance models for longitudinal data.
    Yi S; Zhou Y; Pan J
    Biom J; 2021 Jun; 63(5):1072-1085. PubMed ID: 33604890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of using a robust optimality criterion in model based adaptive optimization.
    Strömberg EA; Hooker AC
    J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):317-324. PubMed ID: 28386710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size determination for longitudinal designs with binary response.
    Kapur K; Bhaumik R; Tang XC; Hur K; Reda DJ; Bhaumik DK
    Stat Med; 2014 Sep; 33(22):3781-800. PubMed ID: 24820424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the use of in-silico simulations to support experimental design: A case study in microbial inactivation of foods.
    Garre A; Peñalver-Soto JL; Esnoz A; Iguaz A; Fernandez PS; Egea JA
    PLoS One; 2019; 14(8):e0220683. PubMed ID: 31454353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.